Pfizer’s Xeljanz (tofacitinib), used to treat conditions such as rheumatoid arthritis and ulcerative colitis, has... read more
Wed, 02/20/19 - 11:50 am
admin
On 2/19/18 Kaleido Biosciences filed for a $120 Million IPO. The company will offer 4,761,905 shares of common stock. The expected price is between $20 and $22 per share. The shares will be... read more
CStone Pharmaceuticals is seeking to raise $282 Million in its upcoming Hong Kong IPO. The company's investors include Boyu Capital, Sequoia Capital, Oriza Holdings, and GIC.
The company... read more
5AM Venture Management, LLC (5AM) of San Francisco, CA and Boston, MA announced on 2/13/19 the closing of two new venture capital funds, totaling $497 million in committed capital. The capital was... read more
Cirius Therapeutics has updated it filing for a planned $86 million IPO. The date of the IPO still hasn't been set.
Cirius' lead candidate, MSDC-0602K, is a once daily, oral treatment for... read more
Ascletis Pharma Inc. (Ascletis, 1672.HK) and 3-V Biosciences, Inc. (3-V Biosciences) jointly announced on 2/13/19 that Ascletis, through its subsidiary, and 3-V Biosciences have entered into an... read more
Beginning on March 1, China will reduce the VAT on a group of 21 rare disease drugs from 16% to 3%. The government's announcement did not specify which drugs would be in the group. The move may... read more
Yuhan Corporation (000100.KS; Yuhan) and Sorrento Therapeutics (Nasdaq: SRNE) announced on 2/12/19 that ImmuneOncia, a joint venture formed in September 2016, has completed a private equity... read more
Xeris Pharmaceuticals announced on 2/11/19 that it filed a registration statement with the Securities and Exchange Commission (the “SEC”) relating to a proposed public offering of 5,000,000 shares... read more
Seattle Genetics (Nasdaq:SGEN) announced on 2/11/19 that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the marketing... read more
Shockwave Medical filed for its IPO on 2/8/19. While the filing did not list the number of shares to be offered or the expected offering price, the offering will bring in an expected maximum of $... read more
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced on 2/8/19 that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation... read more
HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, launched today with $60.75M in Series A funding led by ARCH Venture Partners.... read more
Vaxart has filed for an upcoming stock offering with the number of shares yet to be announced. Vaxart is developing oral vaccines based on it proprietary oral recombinant vaccine technology. The... read more
Sunstone Life Science Ventures today announced the first closing of its Sunstone Life Science Ventures Fund IV ("Sunstone LSV IV") at $91 million. The investment strategy of the new fund is a... read more
Indivior PLC (LON: INDV) (“Indivior” or the “Company”) announced on 2/2/19 that it has entered into a definitive agreement to divest its rights related to the Sai Bo Song (buprenorphine, naloxone... read more
Harpoon Therapeutics announced that it will raise up to $93 million in its IPO. The company is offering 5,400,000 shares and is granting underwriters the option to purchase up to an additional 810... read more
Avedro, Inc. (“Avedro”), a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or... read more